Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Clinical value and indication for the dissection of lymph nodes posterior to the right recurrent laryngeal nerve in papillary thyroid carcinoma.

Luo DC, Xu XC, Ding JW, Zhang Y, Peng Y, Pan G, Zhang W.

Oncotarget. 2017 Aug 16;8(45):79897-79905. doi: 10.18632/oncotarget.20275. eCollection 2017 Oct 3.

2.

Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice.

Sherwood JL, Brown H, Rettino A, Schreieck A, Clark G, Claes B, Agrawal B, Chaston R, Kong BSG, Choppa P, Nygren AOH, Deras IL, Kohlmann A.

ESMO Open. 2017 Sep 28;2(4):e000235. doi: 10.1136/esmoopen-2017-000235. eCollection 2017.

3.
4.

Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto's Thyroiditis.

Zhang Q, Liu BJ, Ren WW, He YP, Li XL, Zhao CK, Zhang YF, Yue WW, Zheng JY, Xu HX.

Sci Rep. 2017 Jul 7;7(1):4899. doi: 10.1038/s41598-017-05153-y.

5.

A simple, fast and inexpensive method for mutation scanning of CFTR gene.

Figueredo Lago JE, Armas Cayarga A, González González YJ, Collazo Mesa T.

BMC Med Genet. 2017 May 25;18(1):58. doi: 10.1186/s12881-017-0420-9.

6.

Exploring the impact of EGFR T790M neighboring SNPs on ARMS-based T790M mutation assay.

Xu S, Duan Y, Lou L, Tang F, Shou J, Wang G.

Oncol Lett. 2016 Nov;12(5):4238-4244. Epub 2016 Sep 26.

7.

Comparison of Epidermal Growth Factor Receptor Mutations between Metastatic Lymph Node Diagnosed by EBUS-TBNA and Primary Tumor in Non-Small Cell Lung Cancer.

Kang HJ, Hwangbo B, Lee JS, Kim MS, Lee JM, Lee GK.

PLoS One. 2016 Sep 29;11(9):e0163652. doi: 10.1371/journal.pone.0163652. eCollection 2016.

9.

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.

Sun J, Zhang J, Lu J, Gao J, Ren X, Teng L, Duan H, Lin Y, Li X, Zhang B, Liang Z.

PLoS One. 2016 Apr 11;11(4):e0153319. doi: 10.1371/journal.pone.0153319. eCollection 2016.

10.

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor.

Wang W, Jiang X, Song Z, Zhang Y.

Onco Targets Ther. 2016 Jan 8;9:211-5. doi: 10.2147/OTT.S97100. eCollection 2016.

11.

Value of TIRADS, BSRTC and FNA-BRAF V600E mutation analysis in differentiating high-risk thyroid nodules.

Zhang YZ, Xu T, Cui D, Li X, Yao Q, Gong HY, Liu XY, Chen HH, Jiang L, Ye XH, Zhang ZH, Shen MP, Duan Y, Yang T, Wu XH.

Sci Rep. 2015 Nov 24;5:16927. doi: 10.1038/srep16927.

12.

Nevospheres from neurocutaneous melanocytosis cells show reduced viability when treated with specific inhibitors of NRAS signaling pathway.

Basu D, Salgado CM, Bauer BS, Johnson D, Rundell V, Nikiforova M, Khakoo Y, Gunwaldt LJ, Panigrahy A, Reyes-Múgica M.

Neuro Oncol. 2016 Apr;18(4):528-37. doi: 10.1093/neuonc/nov184. Epub 2015 Sep 9.

13.
14.

Epidermal growth factor receptor mutation analysis in cytological specimens and responsiveness to gefitinib in advanced non-small cell lung cancer patients.

Li L, Zhang Z, Bie Z, Wang Z, Zhang P, Nie X, Li Y, Wang H, Ai B, Cheng G.

Chin J Cancer Res. 2015 Jun;27(3):294-300. doi: 10.3978/j.issn.1000-9604.2015.05.03.

15.

Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations.

Vliegen L, Dooms C, De Kelver W, Verbeken E, Vansteenkiste J, Vandenberghe P.

Diagn Pathol. 2015 May 29;10:57. doi: 10.1186/s13000-015-0293-1.

16.

Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Mao C, Yuan JQ, Yang ZY, Fu XH, Wu XY, Tang JL.

Medicine (Baltimore). 2015 May;94(21):e775. doi: 10.1097/MD.0000000000000775. Review.

17.

Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR.

Iwama E, Takayama K, Harada T, Okamoto I, Ookubo F, Kishimoto J, Baba E, Oda Y, Nakanishi Y.

Oncotarget. 2015 Aug 21;6(24):20466-73.

18.

Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer.

Danese E, Minicozzi AM, Benati M, Montagnana M, Paviati E, Salvagno GL, Lima-Oliveira G, Gusella M, Pasini F, Lippi G, Guidi GC.

PLoS One. 2015 May 6;10(5):e0126417. doi: 10.1371/journal.pone.0126417. eCollection 2015.

19.

A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing.

Ellison G, Huang S, Carr H, Wallace A, Ahdesmaki M, Bhaskar S, Mills J.

BMC Clin Pathol. 2015 Mar 24;15:5. doi: 10.1186/s12907-015-0004-6. eCollection 2015.

20.

KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.

Xu JM, Liu XJ, Ge FJ, Lin L, Wang Y, Sharma MR, Liu ZY, Tommasi S, Paradiso A.

J Exp Clin Cancer Res. 2014 Dec 10;33:104. doi: 10.1186/s13046-014-0104-7.

Supplemental Content

Support Center